Lymphomas & Lymphoid Neoplasia

A collection of features and news articles published in ASH Clinical News related to lymphomas and lymphoid neoplasia.

On location

Bispecific Antibody REGN1979 Shows Promising Efficacy in Relapsed/Refractory Non-Hodgkin Lymphomas

In a small phase I study of patients with relapsed/refractory non-Hodgkin lymphoma (NHL), approximately half of patients responded to treatment with REGN1979, an anti-CD20...
WIB_icon

Evaluating Safety and Efficacy of Venetoclax Plus R-CHOP in Non-Hodgkin Lymphoma

According to results from the phase Ib CAVALLI study, treatment with the oral BCL2 inhibitor venetoclax, combined with standard immunochemotherapy, induced high response rates...

Study Finds Standard R-CHOP Bests Dose-Adjusted EPOCH-R in DLBCL

In an update from the phase III intergroup Alliance/CALGB 50303 trial, treatment with frontline dose-adjusted (DA) EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) failed...

FDA to Close Its Controversial Medical Device Reporting Program

In what is being called a victory for patients and consumers, the U.S. Food and Drug Administration (FDA) said that it is ending its...
WIB_icon

Post-Transplant Pembrolizumab Consolidation Improves PFS in Relapsed/Refractory Hodgkin Lymphoma

In patients with high-risk, relapsed/refractory classical Hodgkin lymphoma (cHL) who have undergone autologous hematopoietic cell transplantation (AHCT), consolidation therapy with the PD-1 inhibitor pembrolizumab...
WIB_icon

New Study Supports “R2” Regimen in Previously Untreated Follicular Lymphoma

The combination of lenalidomide and rituximab, known as the R2 regimen, improved progression-free survival (PFS), time to next treatment (TTNT), and complete response (CR)...

FDA Approves Polatuzumab Vedotin-piiq for Treatment of DLBCL

The U.S. Food and Drug Administration (FDA) has approved the CD79b-directed antibody drug conjugate polatuzumab vedotin-piiq, in combination with bendamustine and rituximab (BR), to...
On location

Nivolumab Associated With High Response Rates in Relapsed/Refractory PMBL

Nearly three-quarters of patients with relapsed/refractory primary mediastinal large B-cell lymphoma (PMBL) responded to treatment with nivolumab plus brentuximab vedotin, according to findings presented...

Catherine Diefenbach: Polatuzumab Vedotin for Follicular Lymphoma

Dr. Diefenbach shares results from a phase Ib/II trial of polatuzumab vedotin plus obinutuzumab and lenalidomide for relapsed/refractory follicular lymphoma.

Is There a Role for AHCT Consolidation in MCL in the Rituximab Era?

The availability of rituximab-containing induction regimens for patients with mantle cell lymphoma (MCL) has improved outcomes, but younger, transplant-eligible patients may benefit from consolidative...

SHARE